Evidence map›Paper›PMID 34189863›Full record

ArticleJournal of the International AIDS Society2021

Estimating the epidemic consequences of HIV prevention gaps among key populations.

Sharmistha Mishra, Romain Silhol, Jesse Knight, Refilwe Phaswana-Mafuya, Daouda Diouf, Linwei Wang, Sheree Schwartz, Marie-Claude Boily, Stefan Baral

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. There is no path to ending AIDS by 2030 without improving human rights.Journal of the International AIDS Society · 2023
    Article
  10. Article
  11. Article
  12. Key populations are the future of the African HIV/AIDS pandemic.Journal of the International AIDS Society · 2021
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sharmistha MishraDepartment of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-8492-5470
Romain SilholMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0002-5750-7609
Jesse KnightInstitute of Medical Sciences, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-0455-5455
Refilwe Phaswana-MafuyaUniversity of Johannesburg, Johannesburg, Gauteng, South Africa.
Daouda DioufEnda Santé, Dakar, Senegal.
Linwei WangLi Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.ORCID 0000-0001-5406-1034
Sheree SchwartzDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Marie-Claude BoilyMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0003-3919-006X
Stefan BaralDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, USA.ORCID 0000-0002-5482-2419

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Examining PrEP use, implementation preferences and the potential for social support to improve PrEP delivery and persistence among female sex workers in Durban, South AfricaR01NR016650 · NINR · JOHNS HOPKINS UNIVERSITY · PI BARAL, STEFAN DAVID · 2016 to 2020
$3.2M
Medical Research Council MR/R015600/1NIAID NIH HHS P30 AI094189NINR NIH HHS R01 NR016650
6 · The paper itself

Abstract

introductionHIV epidemic appraisals are used to characterize heterogeneity and inequities in the context of the HIV pandemic and the response. However, classic measures used in appraisals have been shown to underestimate disproportionate risks of onward transmission, particularly among key populations. In response, a growing number of modelling studies have quantified the consequences of unmet prevention and treatment needs (prevention gaps) among key populations as a transmission population attributable fraction over time (tPAF DISCUSSION: The distribution of onward transmission risks may be defined by who is at disproportionate risk of onward transmission, and under which conditions. The latter reflects prevention gaps, including secondary prevention via treatment: the epidemic consequences of which may be quantified by the tPAF

conclusionsThe next generation of HIV epidemic appraisals has the potential to support a more specific HIV response by characterizing heterogeneity in disproportionate risks of onward transmission which are defined and conditioned on the past, current and future prevention gaps across subsets of the population.

Indexed as

Acquired Immunodeficiency SyndromeEpidemicsHIV InfectionsHumansHIV/AIDSHIV transmissionkey populationsMathematical modelpopulation attributable fraction

Identifiers

PMID34189863
PMCPMC8242976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.